Fig. 1: Identification of RAD51B as a candidate driver for TNBC formation.
From: RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion
A Kaplan–Meier curve showing the mammary tumors-free rate for mice with TNBC tumors in Brca1Co/Co; Wap-Cre and Brca1Co/Co; Wap-Cre; SB; T2Onc3 group. B Kaplan–Meier curve showing the mammary tumors-free rate for mice with TNBC tumors in Fgfr2S252W/+; MMTV-Cre and Fgfr2S252W/+; MMTV-Cre; SB; T2Onc3 group. C A Venn diagram indicates overlapped candidate TNBC driver genes between Fgfr2S252W/+; MMTV-Cre; SB; T2Onc3 mice and Brca1Co/Co; Wap-Cre; SB; T2Onc3 mice. D Schematic of the reporter screening assays to identify candidate TNBC driver genes. E Heatmap reveals that Rad51b was listed as the most effective TNBC driver gene. *P < 0.05, **P < 0.01, ***P < 0.001. F The expression of RAD51B in human and mouse breast cancer cell lines was measured by western blotting. G Identification of 20 tumors from patients with RAD51B loss-of-function mutations and their molecular subtypes from the TCGA database. H Kaplan–Meier survival plots showing overall survival of breast cancer patients with high or low RAD51B expression.
